Breakthrough Device Designation: What It Actually Means for FDA Review and Medicare Payment

2026-08-05 · Caduvo Team

The FDA Breakthrough Devices Program accelerates review but doesn't guarantee Medicare coverage. Learn the eligibility criteria, real-world benefits during FDA review, and the hard truth about transitional coverage for emerging technologies (TCET) and coding for novel devices.

For a startup with a first-of-its-kind device, the FDA’s Breakthrough Devices Program looks like a fast pass to market — and, founders hope, to reimbursement. The second assumption is wrong. Here is what the designation actually gives you during FDA review, the criteria you have to meet, and the hard truth about what it means for Medicare payment.

The Two-Part Eligibility Test

The designation does not go to just any innovative device. It requires two things. First, the device must “provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating human disease or condition.” Second, it must meet at least one of these three sub-criteria:

Note what is absent: cost reduction or economic value. The program is built on clinical differentiation, not health-economics arguments. Your regulatory lead can request the designation for a pre-submission or even for an IDE. You submit a Q-Submission titled “Request for Breakthrough Device Designation,” with a detailed rationale mapped to the criteria. The FDA responds within 60 days. If it says yes, you are in the program as long as you remain on track to market — the designation can be rescinded if a predicate device gets cleared that changes the competitive landscape.

What You Get During FDA Review

The benefits are process-intensive, not evidence-lite. The FDA will assign a review team and a case manager who stays with your file from submission to decision. You get sprint reviews: focused, interactive meetings on specific topics like clinical study design or biocompatibility testing, held on compressed timelines. You can submit portions of your premarket submission in pieces and get feedback before the full package is loaded. And you get priority review — your submission moves to the front of the queue.

Those perks matter most when the evidence bar is high. A breakthrough device often follows the De Novo pathway for novel, moderate-risk devices that lack a predicate. In those cases, the interactive review can shorten the back-and-forth that typically plagues first-of-kind classifications. A 2023 FDA analysis found that breakthrough-designated devices that went through De Novo averaged 212 days from submission to decision, versus 326 days for non-breakthrough De Novos. Shave four months off a review cycle and your burn rate breathes easier.

The Reimbursement Gap No One Warns You About

This is the pivot point where many founders get burned. Breakthrough designation is an FDA program. Medicare coverage is a CMS decision. The two agencies do not automatically coordinate.

Medicare covers items and services that are “reasonable and necessary” for the diagnosis or treatment of an illness or injury. A device can be FDA-authorized and still get a non-coverage decision from a Medicare Administrative Contractor (MAC). For a startup, that gap can be fatal: you get regulatory approval but no paying patients.

The Centers for Medicare & Medicaid Services recognized this problem and created a voluntary pathway: transitional coverage for emerging technologies (TCET). This program allows certain breakthrough-designated devices to get a national coverage analysis while concurrently generating real-world evidence under coverage with evidence development (CED). Only a narrow slice of products qualify: the device must be FDA-market-authorized, fall within a Medicare benefit category, and address a condition where evidence gaps prevent coverage. CMS then publishes an Evidence Preview and solicits public input on the proposed study questions and the protocol for the required prospective study. If the Evidence Preview supports moving forward, CMS conducts a national coverage determination that covers the device during the evidence-generation period — typically a three- to five-year window.

Do not confuse TCET with a guarantee. CMS accepted only three TCET applications in the program‘s first group announced in June 2024. A MAC can still issue a non-coverage decision while you wait for a national determination. And TCET does not issue a temporary code — you still need to solve for coding separately. The reality: breakthrough designation opens the TCET door an inch, but you have to push it the rest of the way with a detailed evidence plan and a clear theory of why real-world collection will fill the evidence gap.

Coding: The Practical Bottleneck

Most breakthrough-designed devices enter the market without a dedicated HCPCS code. Without a code, no one can bill for it accurately. You have two main options. One: use a miscellaneous or “not otherwise classified” code while you submit an application for a new Level II HCPCS code. This causes payment delays, manual claims review, and higher denial rates. Two: pursue a Category III CPT code through the American Medical Association — a process that takes 12 to 18 months and requires published evidence of clinical utility. Many startups run both tracks in parallel.

In the TCET pathway, CMS expects you to have a code before coverage begins. If you wait until after FDA authorization to start the coding process, you have added at least a year before a Medicare patient can get reimbursed for your procedure. Smart teams file the HCPCS application as soon as the FDA accepts the premarket submission.

What You Should Do Right Now

Short Takeaways

Related reading